Table 2. The inhibitory effects of BMA-155Cl on the growth of HepG-2 xenografts in nude mice.

Drugs and dosage	Mice number (n)	Body weight (g) (initial/end)	Tumor weight (g) (mean±SD)	Tumor weight inhibition (%)	Tumor volume (mm3) (initial/end)	Tumor volume inhibition (%)
Vehicle	6	22.3±1.0/21.9±1.8	1.43±0.62	–	53.8±17.34/465.9±40.6	–
Vincristine (0.4 mg/kg)	6	21.8±1.6/17.1±1.7**	0.52±0.37*	63.6	61.2±16.3/152.4±21.8*	77.9
BMA-155Cl (10 mg/kg)	6	21.9±2.1/22.7±2.5	0.98±0.33*	31.5	50.0±18.0/319.7±26.0*	34.6
BMA-155Cl (20 mg/kg)	6	22.1±1.4/20.2±1.8	0.70±0.24*	51.0	51.1±16.3/218.5±38.8*	59.4

Established tumors were treated with BMA-155Cl by injection intraperitoneally. Body weight and tumor volume were examined before and after drug administration. Tumor weight was measured after mice were sacrificed. Tumor weight inhibition (%)=(1−tumor weight of experimental group/tumor weight of vehicle group)×100%; Tumor volume inhibition (%)=(1−tumor growth volume of experimental group/tumor growth volume of vehicle group)×100%. Note: tumor growth volume=tumor volume (end)–tumor volume (initial). ^*P<0.05, ^**P<0.01 vs vehicle.